# US 2024/0003906 A1 · Biomarker of Fibrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0003906 A1
- Document ID: US20240003906A1
- Status: Published application
- Kind: A1
- Application number: 17/919,270
- Filed: 2020-04-15
- Published: 2024-01-04
- Earliest claimed: 2020-04-15
- Assignees: Nordic Bioscience A/S
- Applicants: Nordic Bioscience A/S
- Inventors: Martin Pehrsson; Morten Asser Karsdal; Diana Julie Leeming; Mette Juul Fisker; Tina Manon-Jensen; Joachim Høg Mortensen
- Web page: https://patentgrep.com/patent/US20240003906A1

## CPC

- G01N 33/6887: {from muscle, cartilage or connective tissue}
- C07K 16/18: against material from animals or humans
- G01N 33/575: for cancer
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- G01N 2333/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- G01N 2470/04: Sandwich assay format
- G01N 2800/065: Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
- G01N 2800/085: Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N 2800/7052: Fibrosis
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to a sandwich immunoassay and kits for detecting in a biological sample cross-linked CTX-III, and its use in evaluating the efficacy of drugs targeting lysyl oxidases (LOXs). Cross-linked CTX-III can be used as a biomarker in diseases associated with fibrosis, including liver fibrosis, chronic intestinal disease, eosinophilic esophagitis and cancer.

## Claims

### Claim at position 1

1: A monoclonal antibody that specifically recognises and binds to a peptide having the C-terminus amino acid sequence KAGGFAPYYG (SEQ ID NO: 1).

### Claim at position 2 (depends on 1)

2: The monoclonal antibody of claim 1, wherein the monoclonal antibody is a monoclonal antibody raised against a synthetic peptide having the C-terminus amino acid sequence KAGGFAPYYG (SEQ ID NO: 1).

### Claim at position 3 (depends on 1)

3: The monoclonal antibody of claim 1, wherein the antibody does not specifically recognise or bind to a peptide having the C-terminus amino acid sequence KAGGFAPYYGX (SEQ ID NO: 2), wherein X represents any amino acid, the C-terminus amino acid sequence KAGGFAPYYGD (SEQ ID NO: 4) or the C-terminus amino acid sequence KAGGFAPYY (SEQ ID NO: 5).

### Claim at position 4

4-5. (canceled)

### Claim at position 5

6: A sandwich immunoassay for detecting in a biological sample cross-linked CT-III, said cross-linked CT-III comprising at least two strands of CT-III joined together by inter-strand cross-linking, said method comprising:
contacting said biological sample comprising said cross-linked CT-III with a first monoclonal antibody bound to a surface, wherein each strand of CT-III comprised in the cross-linked CT-III comprises a C-terminal neo-epitope of CT-III generated by C-protease cleavage of intact type III collagen;
adding a second monoclonal antibody; and
determining the amount of binding of said second monoclonal antibody;
wherein both said first monoclonal antibody and said second monoclonal antibody are specifically reactive with said C-terminal neo-epitope of CT-III, said neo-epitope being comprised in a C-terminal amino acid sequence KAGGFAPYYG-COOH (SEQ ID NO: 1).

### Claim 7

(canceled)

### Claim at position 7 (depends on 6)

8: The sandwich immunoassay of claim 6, wherein the sandwich immunoassay is used to quantify the amount of cross-linked CT-III in a biological sample.

### Claim at position 8 (depends on 6)

9: The sandwich immunoassay of claim 6, wherein the biological sample is a biofluid selected from the group consisting of serum, plasma, urine, amniotic fluid, tissue supernatant, and cell supernatant.

### Claim at position 9

10-11. (canceled)

### Claim at position 10 (depends on 6)

11: The sandwich immunoassay of claim 6, wherein the second monoclonal antibody is labeled, is linked to a fluorophore or is an enzyme-linked antibody.

### Claim 15

(canceled)

### Claim at position 12 (depends on 6)

16: The sandwich immunoassay of claim 6, wherein a further labeled antibody which recognises the second monoclonal antibody is used to determine the amount of binding of said second monoclonal antibody.

### Claim at position 13 (depends on 8)

17: The sandwich immunoassay of claim 8, further comprising correlating the quantity of cross-linked CTIII determined by said method with standard disease samples of known disease severity to evaluate the severity of a disease.

### Claim at position 14 (depends on 8)

18: The sandwich immunoassay of claim 8, further comprising quantifying the amount of PRO-C3 present in the biofluid sample, determining the ratio of cross-linked type III collagen (CTX-III) to N-terminal propeptide of type III collagen (PRO-C3).

### Claim at position 15 (depends on 18)

19: The sandwich immunoassay of claim 18, further comprising correlating the ratio of cross-linked type III collagen (CTX-III) to N-terminal propeptide of type III collagen (PRO-C3) determined by said method with standard disease samples of known disease severity to evaluate the severity of a disease.

### Claim at position 16

20-23. (canceled)

### Claim at position 17 (depends on 20)

24: The sandwich immunoassay of claim 20, wherein the disease is non-alcoholic fatty liver disease, an HCV related liver disease, Crohn's disease, ulcerative colitis, breast cancer, bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer, pancreatic cancer, stomach cancer, ovarian cancer, liver cancer, prostate cancer, or melanoma.

### Claim 25

(canceled)

### Claim at position 19 (depends on 6)

26: A method for evaluating the efficacy of an antagonist drug targeting lysyl oxidases (LOXs), wherein said method comprises using the sandwich immunoassay of claim 6 to quantify the amount of cross-linked CT-III in at least two biological samples, said biological samples having been obtained from a subject at a first time point and at at least one subsequent time point during a period of administration of the antagonist drug to said subject, and wherein a reduction in the quantity of cross-linked CT-III from said first time point to said at least one subsequent time point during the period of administration of the antagonist drug is indicative of an efficacious antagonist drug targeting LOXs.

### Claim at position 20 (depends on 26)

27: The method of claim 26, wherein the method evaluates the efficacy of an antagonist drug targeting LOXL2.

### Claim at position 21 (depends on 1)

28: A kit for use in a sandwich assay, the kit comprising:
a solid support to which is bound the first monoclonal antibody as defined in claim 1; and
the second monoclonal antibody as defined in claim 1, said second monoclonal antibody comprising a label.

### Claim at position 22 (depends on 6)

29: A method of identifying a patient with a fibrotic disease, the method comprising using the sandwich immunoassay of claim 6 to quantify the amount of cross-linked CT-III in a biofluid sample obtained from the patient, and correlating said amount of cross-linked CT-III with i) values associated with known patients with the fibrotic disease and/or normal healthy controls and/or ii) a predetermined cut-off value.

### Claim at position 23 (depends on 29)

30: The method of claim 29, wherein the fibrotic disease is fibrosis and the method identifies the fibrosis response phenotype of the patient, said method further comprising quantifying the amount of N-terminal propeptide of type III collagen (PRO-C3) present in the biofluid sample, determining the ratio of cross-linked type III collagen (CTX-III) to N-terminal propeptide of type III collagen (PRO-C3), and correlating said ratio of cross-linked type III collagen (CTX-III) to N-terminal propeptide of type III collagen (PRO-C3) with a predetermined cut-off value.

### Claim at position 24 (depends on 29)

31: The method of claim 29, wherein the cut-off value is at least 3.8 ng/mL cross-linked CT-III and/or a ratio of cross-linked type III collagen (CTX-III) to N-terminal propeptide of type III collagen (PRO-C3) of at least 0.5.

### Claim at position 25 (depends on 29)

32: The method of claim 29, wherein the fibrotic disease is eosinophilic esophagitis, a chronic intestinal disease, a cancer, or fibrosis.

### Claim 35

(canceled)

### Claim at position 27 (depends on 29)

36: The method of claim 29, wherein said method identifies a patient who would benefit from a treatment with a medicament which targets collagen cross-linking.

### Claim 37

(canceled)
